Patients often develop nausea, vomiting and bloating after bone marrow transplantation (BMT). These symptoms may interfere with nutrition and the ability to take oral medications. Gastroparesis is a recognized cause of these symptoms in non-transplant patients but less is known about patients who undergo BMT. Between January 1996 and March 1997, a total of 151 patients underwent BMT. Eighteen patients (12%) developed persistent symptoms suggestive of gastroparesis (persistent nausea, vomiting or bloating). Scintigraphic gastric emptying studies were performed to assess for gastroparesis. Prokinetic agents were administered at the time of study. The records on these patients were compared with those of all other patients undergoing BMT during the same time period without these symptoms. Nine patients who demonstrated delayed gastric emptying were further evaluated with esophagastroduodenoscopy and biopsy. Biopsy samples were reviewed for evidence of graft-versus-host disease (GVHD). Fourteen of 18 patients demonstrated delayed gastric emptying and most responded to prokinetic agents given at the time of study. Age, conditioning regimen, cytomegalovirus antigenemia and acute GVHD did not appear to be associated with the development of gastroparesis. Allogeneic BMT recipients were at higher risk than autologous BMT patients (26% vs 0%, P Ͻ 0.0001). Of allogeneic BMT recipients, there was a nonsignificant trend of patients receiving tacrolimus to be less likely to experience gastroparesis than those receiving cyclosporine (27% vs 48%, P = 0.08). For the nine patients undergoing upper endoscopy, GVHD on gastric biopsy was an uncommon finding and was mild when present. Gastroparesis appears to be a common cause of nausea, vomiting and bloating following allogeneic BMT. This may occur less often with tacrolimus than cyclosporine because of the former agent's prokinetic properties. Patients usually respond to prokinetic drugs at the time of scintigraphy. GVHD and CMV infection do not appear to be major contributing factors. Bone Marrow Transplantation (2001) 28, 59-62.
Following bone marrow transplantation (BMT), some patients develop persistent nausea, vomiting, bloating, early satiety and decreased tolerance to oral nutrition and medications. These symptoms frequently develop weeks after transplantation and inhibit weight gain, optimal nutrition and the transition from intravenous to oral medications.
Gastroparesis is a disorder of motor function of the stomach in which gastric emptying is delayed. Patients with gastroparesis often develop symptoms of nausea, vomiting, bloating and distension. Gastroparesis has many known causes which include atrophic gastritis, diabetes, hypothyroidism, uremia, scleroderma, anticholinergics and stress. 1 Additionally, cytomegalovirus (CMV), herpes simplex virus (HSV) and other viral infections have been implicated as causes of delayed gastric emptying. 1, 2 We performed gastric emptying studies on patients presenting with persistent nausea, vomiting and bloating following allogeneic or matched unrelated donor transplantation to assess for underlying gastroparesis and to ascertain which factors were associated with the development of gastroparesis.
Methods

Patients
Between January 1996 and March 1997, all patients who presented after resolution of the acute toxicities of the conditioning regimen with persistent symptoms of nausea, vomiting, bloating or early satiety at the University of Florida BMT clinic or inpatient unit were evaluated with Technetium 99m-labeled egg scintigraphy. The study was performed by the method described by Johnson et al 3 with modifications by Fahey et al. 4 A delay in gastric emptying was defined as a gastric emptying half-time of greater than 90 min. Intravenous erythromycin and/or metochlopramide doses were frequently administered during these studies to assess their effect on gastric motility. 5 A new gastric emptying half-time was determined after administration of these agents. If the slope of the gastric emptying half-time did not change, then this was reported as no response. Nine of the patients who were found to have delayed gastric emptying were further evaluated with esophagogastroduodenoscopy and biopsy. The decision to perform endoscopy was based on the recommendations of the consulting gastroenterologist and was often to look for possible infectious etiologies.
Pathology
Biopsy samples were reviewed by pathologists at the University of Florida and the University of Minnesota for the presence and grading of possible GVHD. All gastric biopsies were fixed in buffered formalin and processed routinely. At least two hematoxylin and eosin-stained slides were reviewed for each case. The diagnosis of GVHD was made following the criteria put forth by Snover et al 6 including apoptosis with karyorrhectic debris in glandular epithelium, gland destruction, dilated gastric glands containing eosinophilic granular debris and a sparse lymphocytic infiltrate. The degree of GVHD was quantified using a three-tier grading system of mild, moderate and severe.
Data collection
The records on all patients who underwent scintigraphic assessment were subsequently reviewed. Information extracted from the records included patient age, time to development of symptoms, development of acute clinical GVHD at any site, conditioning regimen, immunosuppressive regimen, CMV antigenemia within 8 weeks of scintigraphic assessment and biopsy results from endoscopy, if performed. Additionally, the records were reviewed for all other patients undergoing allogeneic and matched unrelated donor transplant during the same time period. Data extracted from the records for these patients included the type of conditioning regimen, immunosuppressive regimen, presence of acute clinical GVHD at any site and cytomegalovirus antigenemia.
Results
A total of 151 patients aged 17 years or older underwent BMT at the University of Florida during the study period. Ninety-seven received autologous or stem cell transplantation, 34 received allogeneic sibling matched transplantation and 20 received matched unrelated donor (MUD) transplantation. Eighteen patients (12%) developed signs and symptoms suggestive of gastroparesis following transplantation. Clinical characteristics and results of scintigraphic assessment of these patients are presented in Table 1 .
Fourteen of the 18 patients demonstrated delayed gastric emptying on scintigraphy and were confirmed to have gastroparesis. None of the 97 autologous BMT recipients developed gastroparesis compared to 14 of the 54 allogeneic BMT recipients (26%, P Ͻ 0.00001). Median onset was 54 days following transplantation, but presentation was as early as 34 days or as late as 113 days following transplant. The median time to development of symptoms in symptomatic patients evaluated for gastroparesis was shorter for those confirmed to have delayed emptying time on scintography compared with those who were found to have normal gastric emptying (54 vs 112 days; P = 0.011) (Mann-Whitney U test used for calculation of differences with small numbers).
Degree of the delay in gastric emptying, as well as magnitude of response to prokinetic agents for patients demonstrating delayed gastric emptying are given in Table 2 and illustrated in Figure 1 . All 11 patients who received erythromycin responded (100%), while eight of 12 patients who received metoclopramide responded (67%). For most patients, erythromycin accelerated gastric emptying much more than metoclopramide.
Nine patients with delayed gastric emptying by scintigraphic assessment underwent upper endoscopy. These results are presented in Table 3 . Most patients had endoscopic evidence of gastritis (n = 6) or other types of inflammation (n = 3) on visual inspection. Two patients had mild acute GVHD and two others had histologic findings suggestive of but not definitive of GVHD. None showed histologic evidence of CMV or HSV gastritis. No consistent biopsy findings were apparent for patients demonstrating gastroparesis.
Use of total body irradiation in the conditioning regimen, age, acute clinical GVHD at any site and CMV antigenemia were not associated with the development of gastroparesis (Table 4) . Of patients developing gastroparesis, only two of 14 (14%) patients had undergone transplantation from an unrelated donor (Table 5 ). Of patients not developing gastroparesis, 18 of 40 (45%) had undergone transplantation from an unrelated donor. Patients developing gastroparesis were less likely to have undergone transplantation from an unrelated donor: 14% vs 45% (P = 0.038). Of the 20 patients who underwent transplantation from an unrelated donor, 16 (75%) of these patients received tacrolimus. Of the 34 patients who underwent matched sibling transplant, six (17%) received tacrolimus. Of the patients with gastroparesis, three of 14 (21%) received tacrolimus. Of the patients who did not develop gastroparesis, 19 of 40 (47%) received tacrolimus. There was a trend toward less gastroparesis for patients receiving tacrolimus as part of the immunosuppressive regimen: 21% vs 47% (P = 0.08).
Discussion
Following matched sibling or matched unrelated donor transplantation, patients occasionally develop persistent nausea, vomiting, bloating and lack of appetite long after the acute toxicities of the conditioning regimen abate. This study suggests that these symptoms are often due to delayed gastric emptying and that gastroparesis should be considered in the differential diagnosis. Twenty-six percent of allogeneic patients who underwent bone marrow transplantation during the study period demonstrated delayed gastric emptying by scintigraphy, indicating that this entity is common.
Delayed gastric emptying has many potential etiologies. Those etiologies which have been previously described and may be causative in the setting of BMT include stress, viral infection including both CMV and HSV, and medication side-effects such as anticholinergic effects or anti-motility Cy = cyclophosphamide; TBI = total body irradiation; Melph = Melphelan; Ara-C = cytarabine; CsA = cyclosporine; MUD = matched-unrelated; ND = not done; Y = yes.
a Short-course methotrexate was also given to all patients. effects of opiates. 1 Other plausible etiologies related to transplantation include autonomic neurologic damage secondary to the preparative regimen or GVHD. Gastroparesis has been described in recipients of solid organ transplants and in patients undergoing autologous transplantation. [7] [8] [9] [10] No clear etiology has been found in patients receiving solid organ transplants while chemotherapy effects have been postulated as a potential cause in stem cell transplant patients. [7] [8] [9] [10] Signs and symptoms of gastroparesis occurred only in patients receiving allogeneic or matched unrelated donor transplants in our study.
Based on our review of the literature, clinical gastroparesis is not a commonly recognized side-effect of either cyclosporine or tacrolimus. However, in patients who have received renal transplants, gastric emptying is significantly Metoclopramide given Erythromycin given Figure 1 The degree of delay in the gastric emptying, as well as the magnitude of response to prokinetic agents, for patients demonstrating delayed gastric emptying. In this scan, there was no emptying spontaneously or after a metoclopramide challenge, as evidenced by no drop in counts, but a prompt, precipitous emptying after erythromycin administration.
faster in patients receiving tacrolimus compared with patients receiving cyclosporine. 11 In that study, gastric emptying times were normal in all patients studied and cyclosporine-treated patients only had relatively slower gastric emptying. This result may have been secondary to prokinetic properties of tacrolimus which is a macrolide.
11
Only three of 14 patients in our study with delayed gastric emptying received tacrolimus, with a trend toward less gastroparesis for patients receiving tacrolimus when compared with patients taking other types of immunosuppression.
Scleroderma is an autoimmune disease known to cause gastroparesis and has many shared clinical features with chronic GVHD. 1 Mild GVHD was documented in some gastric biopsies, but was not a consistent finding and seems unlikely to be a major causative factor. Additionally, the lower incidence of delayed gastric emptying in matched- unrelated donor transplant patients (5% vs 38%) further suggests that GVHD is not the major contributory factor to the development of gastroparesis. Our institutional practice is to favor tacrolimus over cyclosporine for patients receiving matched-unrelated donor transplants. The prokinetic properties of tacrolimus may explain the decreased incidence of gastroparesis for patients receiving matched-unrelated donor transplants. 11 The presence of CMV viremia did not appear to be related to the finding of delayed gastric emptying on scintigraphic assessment and viral cytopathic changes were not seen in gastric biopsy specimens.
Our findings suggest that delayed gastric emptying is a potential cause of persistent nausea, vomiting and other symptoms of dyspepsia following transplant. Patients usually respond to prokinetic agents. For patients with signs and symptoms of gastroparesis following allogeneic BMT, further evaluation with scintigraphic assessment or an empiric trial of prokinetics would be reasonable. No sole causative factor could be identified, although the use of immunosuppression other than tacrolimus may be contributory. The retrospective design of this study limits strong inferences from our data. Further prospective studies designed to elucidate the cause of gastroparesis and assess the clinical response to prokinetic agents are needed.
